At ASCO 2017, 195 abstracts in the feld of respiratory oncology were presented (169 in 2016): 22 oral presentations (including 4 in a clinical science symposium), 24 poster discussion items, and 149 posters. In this summary, most attention will go to phase III randomized controlled trials (RCTs) and innovative data that are, or may become, relevant for the practicing clinician. As this report is only the “extract of the abstracts”, the reader is referred to the respective abstracts published in J Clin Oncol volume 35 Suppl 15, 2017 (abstracts #8500–8586 and #9000–9107 and available on-line at